Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Open in API
Filings indexed 740 across all filing types
Latest filing 2024-02-07 Board/Management Inform…
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
424B3
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Spyre Therapeutics, Inc. It includes announcements of a material definitive agreement (indemnification agreement), resignation and appointment of directors, amendments to bylaws, adoption of a new code of conduct, and amendments to an employment agreement. The content focuses on corporate governance changes, director appointments, and amendments to company policies rather than financial results or detailed financial statements. The presence of director resignation and appointment, amendments to bylaws, and code of conduct updates aligns with Board/Management Information filings. The document is not an Annual Report, Earnings Release, or any financial report type. It is not a proxy statement or voting results announcement. Therefore, the best classification is Board/Management Information (MANG). The document length and detail support a high confidence score.
2024-02-07 English
4
Director's Dealing
2024-02-05 English
3
Director's Dealing
2024-02-05 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes the adoption of an indemnification agreement, resignation and appointment of directors, amendments to employment agreements, amendments to bylaws, adoption of a new code of conduct, and related exhibits. There are no financial statements or detailed financial performance data included. The primary focus is on management and board changes, governance updates, and related agreements. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document length is substantial and contains detailed disclosures typical of an 8-K related to management and governance changes, not a full annual or quarterly report or other categories.
2024-02-05 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from a company (Spyre Therapeutics, Inc.) to the SEC staff comments on a Registration Statement on Form S-1. It addresses specific SEC comments on disclosures, risk factors, and regulatory matters related to the company's planned public offering. The document references the Registration Statement on Form S-1, which is a filing used for initial public offerings (IPOs) and other securities registrations. This is not a financial report like an Annual Report (10-K) or Quarterly Report (IR), nor is it an earnings release or management discussion. It is a regulatory correspondence responding to SEC comments on a registration filing. Such correspondence is best classified under Regulatory Filings (RNS), as it is a regulatory compliance document that does not fit into other specific categories like financial reports or governance disclosures.
2024-02-03 English
4
Director's Dealing
2024-02-03 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.